Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin and Allo-SCT in Advanced Renal Cell Carcinoma
NCT00006968Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2000
- Primary completion
- Sep 2004
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentostatin in renal cell carcinoma (RCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Duration and efficiency of hematopoietic and immunologic engraftment, Hematologic and non-hematologic toxic effects and 2 more. Started Sep 2000; status: completed.
02
Drugs
pentostatin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00006968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006968.